Next Article in Journal
Recent Progress of Basic Studies of Natural Products and Their Dental Application
Next Article in Special Issue
Pilot Studies on Two Complementary Bath Products for Atopic Dermatitis Children: Pine-Tar and Tea
Previous Article in Journal
Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial
Previous Article in Special Issue
Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

Medicinal Cannabis—Potential Drug Interactions

NICM Health Research Institute, Western Sydney University, Westmead, NSW 2145, Australia
Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
Authors to whom correspondence should be addressed.
Medicines 2019, 6(1), 3;
Received: 30 November 2018 / Revised: 19 December 2018 / Accepted: 21 December 2018 / Published: 23 December 2018
(This article belongs to the Special Issue Safety of Complementary Medicines)
The endocannabinoids system (ECS) has garnered considerable interest as a potential therapeutic target in various carcinomas and cancer-related conditions alongside neurodegenerative diseases. Cannabinoids are implemented in several physiological processes such as appetite stimulation, energy balance, pain modulation and the control of chemotherapy-induced nausea and vomiting (CINV). However, pharmacokinetics and pharmacodynamics interactions could be perceived in drug combinations, so in this short review we tried to shed light on the potential drug interactions of medicinal cannabis. Hitherto, few data have been provided to the healthcare practitioners about the drug–drug interactions of cannabinoids with other prescription medications. In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters (Glycoprotein p, breast cancer resistance proteins, and multidrug resistance proteins) and metabolizing enzymes (Cytochrome P450 and UDP-glucuronosyltransferases). Caution should be undertaken to closely monitor the responses of cannabis users with certain drugs to guard their safety, especially for the elderly and people with chronic diseases or kidney and liver conditions. View Full-Text
Keywords: Cannabis; cannabinoids; THC; CBD; drug–drug interactions; pharmacokinetic; cytochrome P450; UDP-glucuronosyltransferases; glycoprotein p; BCRP; MRPs Cannabis; cannabinoids; THC; CBD; drug–drug interactions; pharmacokinetic; cytochrome P450; UDP-glucuronosyltransferases; glycoprotein p; BCRP; MRPs
Show Figures

Graphical abstract

MDPI and ACS Style

Alsherbiny, M.A.; Li, C.G. Medicinal Cannabis—Potential Drug Interactions. Medicines 2019, 6, 3.

AMA Style

Alsherbiny MA, Li CG. Medicinal Cannabis—Potential Drug Interactions. Medicines. 2019; 6(1):3.

Chicago/Turabian Style

Alsherbiny, Muhammad A., and Chun G. Li. 2019. "Medicinal Cannabis—Potential Drug Interactions" Medicines 6, no. 1: 3.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop